Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues.
To investigate HER-2/neu oncoprotein immunoreactivity, monoclonal antibody TA1 immunohistochemical examination of flash-frozen radical prostatectomy specimens was performed (n = 35). All prostatic specimens contained benign prostatic hyperplasia (BPH) and/or prostatic intraepithelial neoplasia (PIN), as well as prostatic carcinoma (CaP). HER-2/neu oncoprotein immunoreactivity in BPH tissues was not significantly different than that for the PIN basal cell layer (P = 0.10) or for the PIN luminal cells (P = 0.17). There was significantly more HER-2/neu oncoprotein immunoreactivity in BPH than in areas of CaP (P < 0.001). There was no significant difference in the amount of immunoreactivity present in PIN basal cells when compared to the PIN luminal cells (P = 0.49). Both the PIN basal cells and luminal cells stained for the HER-2/neu oncoprotein to a higher degree than cells in the CaP areas (P < 0.001 in both cases). HER-2/neu oncoprotein immunoreactivity is present at a significantly higher degree in BPH and PIN than in malignant prostatic epithelium.
Ibrahim
G K
GK
Division of Urology, Duke University Medical Center, Durham, NC 27710.
MacDonald
J A
JA
Kerns
B J
BJ
Ibrahim
S N
SN
Humphrey
P A
PA
Robertson
C N
CN
D000368:Aged; D002277:Carcinoma / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000378:metabolism*; D011467:Prostate / Q000378:metabolism*; D011470:Prostatic Hyperplasia / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases
D009856:Oncogene Proteins, Viral; D018719:Erb-b2 Receptor Tyrosine Kinases